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Background: The effects of brain natriuretic peptide (BNP) on the risk of cardiovascular disease and atherosclerosis
have been studied. However, little information is available regarding peripheral arterial disease (PAD), particularly
among subjects with type-2 diabetes mellitus (T2DM). The aim of our study was to assess the potential relationship
between BNP levels and PAD among T2DM patients.
Methods: The study cohort was 507 T2DM outpatients in which BNP levels were measured. Cross-sectional associations
between BNP levels (in tertiles) and PAD were examined.
Results: Compared withT2DM patients without PAD, BNP levels were markedly higher in patients with PAD (p = 0.001).
Correlation analyses showed that the BNP level was negatively correlated with the ankle–brachial index (r = −0.453,
p = 0.033). At a cutoff value of 78.2 pg/ml, the BNP level showed a sensitivity of 71.9%, a specificity of 68.1%, and a
positive predictive value of 84.3% for a diagnosis of PAD. The area under the receiver-operating characteristic curve
increased significantly if BNP levels were incorporated into a predictive model of the potential risk factors for PAD (0.85 vs
0.81, p = 0.029).
Conclusions: BNP is a potential and promising biomarker for PAD screening in T2DM patients.
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Peripheral arterial disease (PAD) is a subclinical measure
of atherosclerotic vascular disease and a strong inde-
pendent risk factor for cardiovascular disease (CVD) and
mortality. Type-2 diabetes mellitus (T2DM) is associated
with accelerated atherosclerosis and an increased risk of
PAD. The incidence of PAD in T2DMpatients is high
[1]. Patients with T2DM have a fourfold increased risk
of PAD [2], and the prevalence of PAD is higher in dia-
betic than in non-diabetic populations [3].
Brain natriuretic peptide (BNP) is secreted predomin-
antly from the ventricular myocardium and is a useful
predictor of cardiovascular disease risk [4]. Interestingly,
increasing evidences show that BNP is a useful marker* Correspondence: hanchunmao1@126.com
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unless otherwise stated.not only for cardiac function, but also for other vascu-
lopathies. Increased BNP concentrations have been asso-
ciated with atherosclerosis [5], and their levels been
shown to be elevated in a general population with PAD
[6-8].
The development of PAD is associated with several
risk factors and multiple biomarkers representing vari-
ous etiologic pathways of atherosclerosis [9]. Recent
findings suggest a close relationship between glucose
metabolism and BNP levels. BNP levels were found to
be higher in patients with T2DM and inversely associ-
ated with the risk of T2DM [10-12], though the mechan-
ism is not known. These observations suggested a
potential role of BNP in the development of T2DM with
PAD. However, it is not clear if BNP contributes to redu-
cing or improving the morbidity of PAD in T2DM. To
explore such a possibility, we measured serum BNPThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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BNP levels and PAD among outpatients with T2DM.
Methods
Study patients
The study was approved by the Ethics Committee of the
Second Affiliated Hospital of Zhejiang University (Zhe-
jiang, China). Written informed consent was obtained
from all subjects to participate in this study.
A total of 507 outpatients with T2DM (age ≥18 years)
in the Department of Endocrinology of the Second
Affiliated Hospital of Zhejiang University from January
2012 to January 2013 were recruited. Inclusion criteria
were a diagnosis of T2DM according to criteria set by
the American Diabetes Association [13] and PAD was
defined as arterial insufficiency with an ankle–brachial
index(ABI) ≤0.90 in either leg [14]. Exclusion criteria
were:severe infection (ischemic ulceration/necrosis);
acute or severe and chronic diabetic complications
(diabetic ketoacidosis or coma, diabetic nephropathy,
clinical albuminuria of diabetic nephropathy); poor
glucose control (hemoglobin A1c > 10.0%) or require-
ment of insulin treatment; diseases of the liver or kid-
ney; cancer or autoimmune disease; CVD (including
cardiac systolic and diastolic dysfunction, valvular ab-
normalities, myocardial infarction, or cardiomyopathy,
other structural heart diseases and changes in the electro-
cardiogram due to myocardial ischemia and various ar-
rhythmias); use of diureticsor nitrates; any other condition
that (in the investigator’s judgment) could affect study par-
ticipation or confound data interpretation.
General clinical data and laboratory measurements
Clinical and laboratory data were collected from medical
records. Cardiac contraction and diastolic functions were
evaluated by echocardiography. Diabetic neuropathy was
examined by testing vibration (using a 128-Hz tuning fork),
pin-prick sensation (using Neurotip™; Owen Mumford,
Chipping Norton, UK), temperature sensation (warm and
cool rods), and Achilles tendon reflex (tendon hammer).
Albumin levels were measured in a spot urine sample,
which was collected as the first void in the morning or at
random. The results of albumin measurements in spot col-
lections may be expressed as the urinary albumin-to-
creatinine ratio (UACR). Albuminuria was defined as two
of three the UACR of ≥30 μg/mg on at least two occasions
within 3–6 months [15]. Demographic information (age,
sex, blood pressure (BP), the body mass index (BMI) and
duration of T2DM) was obtained at study baseline. Venous
blood samples were collected from all patients in the morn-
ing after fasting for 10 h and stored at room temperature.
Biochemical parameters such as levels of triglyceride
(TG), total cholesterol (TC), high-density lipoprotein-
cholesterol (HDL-C), low-density lipoprotein-cholesterol(LDL-C), C-reactive protein (CRP), creatinine, uric acid,
and homocysteine were measured using an automated clin-
ical chemistry analyzer (Advia 2400; Siemens, Munich,
Germany). Hemoglobin A1c (HbA1c) levelswere measured
by high-performance liquid chromatography (Variant II;
Bio-Rad, Hercules, CA, USA).
BNP peptide assay
Serum BNP levels were quantified using an electrochemilu-
minescence immunoassay (Advia Centaur XP; Siemens)
with minimum and maximum detectable concentrations of
4.5 pg/ml and 5000 pg/ml, respectively (normal reference
range <100 pg/ml). Tests were undertaken in our clinical
laboratory. Inter- and intra-batch coefficients of variation
were maintained within 5.5% and 3.5%, respectively.
Measurement of the ABI
Measurement of the ABI is a validated, useful and easy
tool to diagnose PAD. ABI measurements were done
with the patient in the supine position. BP was measured
in the bilateral brachial and dorsalis pedis arteries with
an 8-MHz Doppler probe. The ABI was calculated by
dividing the value of the systolic blood pressure (SBP) in
the right or left ankle by the value of the SBP in the
arm.
Definitions
An ABI ≤0.9 was selected as the cutoff value for the
diagnosis of PAD; an ABI >1.3 was selected as the cutoff
value for calcification [14]. Hypertension was defined as
SBP >140 mmHg, or diastolic BP >90 mmHg, or use of
antihypertensive medications [16]. The diagnostic cri-
teria of systolic dysfunction (left ventricular ejection
fraction (EF) <50%) and diastolic dysfunction (E/A ratio
<1or >2) were according to guidelines set by the
European Society of Cardiology for the diagnosis and
treatment of acute and chronic heart failure [17]. The
diagnosis of diabetic neuropathycan be made after a
careful clinical examination [18]. The diagnosis of clin-
ical albuminuria was albuminuria ≥300 μg/mg [15].
Hyperlipidemia was defined as serum TC >6.2 mmol/l
and/or TG >2.3 mmol/l or HDL-C <1.04 mmol/l
(men), <1.17 mg/dl (women), or use of lipid-lowering
agents [19].
Statistical analyses
Data are the mean ± standard deviation (SD) or percent-
age (%) and analyzed using the Student’s t-test or chi-
square test. Age, sex, CRP level, smoking, hypertension,
hyperlipidemia, and duration of T2DM account for most
of the risk associated with the development of PAD [20].
BNP levels did not have a normal distribution, and
were divided into four quartiles for analyses: <26, 26–76,
76–100, and 100–529 pg/ml. Analysis of variance with
Table 1 Baseline characteristics of PAD (ABI ≤ 0.9) and
non–PAD (1.3 ≥ ABI > 0.9) diabetic patients
Variables PAD n = 138 No-PAD n = 369 p value
Male/Female, n 103/35 260/109 0.414
Age (years) 60.9 ± 8.2 59.8 ± 7.7 0.161
BMI 20.22 ± 2.79 20.18 ± 2.66 0.882
Duration of
diabetes (year)
6.3 ± 3.7 5.8 ± 3.2 0.035
ABI 0.78 ± 0.11 1.09 ± 0.12 0.000
Systolic blood
pressure (mmHg)
132.4 ± 12.7 131.7 ± 11.5 0.554
Diastolic blood
pressure (mmHg)
77.7 ± 6.7 78.1 ± 7.4 0.579
HbA1c (%) 7.9 ± 0.9 7.6 ± 0.8 0.034
Serum creatinine (μmol/l) 91.4 ± 7.2 90.9 ± 6.6 0.418
Serum uric acid (μmol/l) 234.7 ± 34.4 229.4 ± 32.7 0.105
UACR (μg/mg) 72.4 ± 27.2 68.5 ± 25.4 0.132
Total cholesterol (mmol/l) 4.87 ± 1.04 4.76 ± 1.11 0.313
Triglycerides (mmol/l) 1.24 ± 0.32 1.21 ± 0.27 0.291
High-density lipoprotein
cholesterol (mmol/l)
1.09 ± 0.21 1.12 ± 0.22 0.167
Low-density lipoprotein
cholesterol (mmol/l)
2.44 ± 0.43 2.39 ± 0.38 0.204
C-reactive protein (mg/l) 5.3 ± 1.1 5.2 ± 1.1 0.432
Fibrinogen (mg/dl) 3.21 ± 0.87 3.14 ± 0.79 0.388
Left ventricular ejection
fraction (%)
61.7 ± 4.6 62.3 ± 5.1 0.227
E/A 1.22 ± 0.24 1.25 ± 0.26 0.547
BNP (median and
interquartile range) (pg/ml)
78 (4.5–529) 71 (5.0–497) 0.001
Hypertension, n (%) 56 (40.58) 137 (37.13) 0.542
Hyperlipidemia, n (%) 58 (42.03) 129 (34..96) 0.142
Current smoking, n (%) 55 (39.86) 141 (38.21) 0.814
RAAS blockade, n (%) 32 (23.19) 81 (21.95) 0.859
Calcium channel blockers,
n (%)
21 (15.22) 62 (16.80) 0.768
Statin therapy, n (%) 27 (19.57) 81 (21.95) 0.644
Aspirin therapy, n (%) 33 (23.91) 102 (27.64) 0.464
Date is expressed as mean ± standard deviation.
BMI, body mass index. ABI, ankle-brachial index. UACR, urinary albumin-to-
creatinine ratio. BNP, brain natriuretic peptide. RASS, renin-angiotensin-
aldosterone system. E, late diastolic filling velocity. A, early diastolic
filling velocity.
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baseline values among the four groups. Logistic regres-
sion models were fitted to calculate the odds ratio
(OR) and 95% confidence interval (CI) for PAD. The
association between serum BNP levels and PAD was
analyzed using multiple regression analysis adjusted
for other CVD risk factors. BNP levelswere highly
skewed, so log10-transformed values were used to de-
termine linear correlation coefficients for the associ-
ation between BNP levelsand the ABI. The predictive
value of BNP levels was assessed by analyses of receiver
operating characteristic (ROC) curves. Area under the
ROC curve was used to compare the accuracy of the
ability to assess the likelihood of PAD between the
models adjusted for potential risk factors with and
without BNP levels.
Data were analyzed using SPSS v15.0 (SPSS, Chicago,
IL, USA). Statistical assessments were two-tailed and p <
0.05 considered significant.
Results
A total of 507 T2DM patients (324 malesand 183 females;
mean age, (60.2 ± 7.2)years) were involved in this study.
The median BNP level was 73 (interquartile range,
4.5–529) pg/ml. A total of 138 patients (27.2%) had PAD.
Patients were placed into two groups based on PAD
and their characteristics are summarized in Table 1. The
median BNP level was significantly higher in the PAD
group than in the non-PAD group (78 [4.5–529] pg/ml
vs. 71 [5.0–497] pg/ml, p = 0.001). Compared with the
non-PAD group, the duration of T2DM and HbA1c
were significantly greater in the PAD group (p = 0.035
and 0.034, respectively). No differences were shown with
respect to age, BP, EF, E/A ratio, smoking habits, the
BMI, the UACR, serum creatinine as well as levels of
CRP, uric acid, fibrinogen, LDL-C, HDL-C and TC (p >
0.05 for all) between the two groups.
The BNP level was negatively correlated with the ABI
(r = −0.453, p = 0.033) (Figure 1). Accordingly, we deter-
mined the significance and magnitude of the association
between the BNP level and PAD. In model 1, after ad-
justment for age and sex, each 1-SD increment in the
BNP level was associated with an increased risk of PAD
(OR, 1.21; 95% CI, 1.19–1.45; p = 0.012). In model 2, after
adjustment for age, sex, the BMI, BP, smoking habit, the
UACR, duration of T2DM, as well as levels of uric acid,
TG, LDL-C, HDL-C,and HbA1c, the trend remained
significant (OR, 1.16; 95% CI, 1.04–1.34; p = 0.021). The
odds of having PAD at baseline increased significantly
with increase in the quartile of the BNP level (Table 2).
In the ROC analysis, BNP yielded an area under the
curve (AUC) of 0.68 (95% CI, 0.62–0.77; p =0.008) for
detection of PAD. A BNP level of 78.2 pg/ml was deter-
mined as the cutoff value that gave the best combinationof sensitivity and specificity (0.719 and 0.681, respect-
ively) (Figure 2A). We determined the effect of the BNP
level on assessment of PAD by comparing the areas
under the ROC curves between risk models with and
without the BNP level (Figure 2B). The AUC associated
with the ROC analysis of model 1 (including age,
sex, the BMI, smoking habit, the UACR, hypertension,
Figure 1 The relationship between log10BNP and ABI (r = −0.453,
p = 0.033).
Table 2 Logistic regression analysis examining BNP
quartiles in relation to prevalence of PAD in diabetic
patients (n = 507)
Group Quartiles of BNP
OR 95% CI p
Model 1 with quartile group
as categorical variables
Group 1 (lowest values) Reference
Group 2 1.13 0.97–1.31 0.062
Group 3 1.19 1.11–1.34 0.018
Group 4 (highest values) 1.31 1.21–1.59 0.011
P for trend 1.22 1.17–1.41 0.015
1 SD change in BNP included
as continuous variable
1.21 1.19–1.45 0.012
Model 2 with quartile group
as categorical variables
Group 1 (lowest values) Reference
Group 2 1.07 0.95–1.21 0.081
Group 3 1.15 1.02–1.31 0.047
Group 4 (highest values) 1.25 1.10–1.43 0.032
P for trend 1.18 1.11–1.35 0.039
1 SD change in BNP included
as continuous variable
1.16 1.04–1.34 0.021
Model 1 was adjusted for age and sex.
Model 2 was adjusted for age, sex, BMI, BP, uric acid, UACR, smoking, TG, LDL-C,
HDL-C, duration of diabetes and HbA1c.
BNP levels were as follows median (25–75% interquartile range): quartile 1,
24.0 (4.5 –25.0) pg/ml; quartile 2, 43.0 (26.5 –75.0) pg/ml; quartile 3, 86.0
(76.5 –100) pg/ml; quartile 4, 146.2 (100.5 –529) pg/ml.
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uric acid, and HbA1c) was 0.81 (95% CI, 0.74–0.87).
Addition of the BNP level increased the AUC to 0.85
(95% CI, 0.77–0.91) (p =0.029 compared with model 1).
Discussion
In the present study, we found a clear association be-
tween the BNP levels and the risk of PAD in T2DM pa-
tients without overt CVD. This association remained
unchanged even after controlling for potential con-
founding risk factors. Importantly, our study revealed
that incorporation of the BNP levels into a model of
potential risk factors significantly improved assessment
of the likelihood of PAD in T2DM patients. This is the
first study providing statistical elucidation of the clin-
ical value of the BNP levels in assessment of the risk of
PAD in T2DM outpatients. These findings highlight
the potential additive value of measurement of the
BNP levels in the risk assessment of PAD in T2DM pa-
tients (especially in patients without overt CVD).
These findings have important clinical implications be-
cause patients with T2DM have an increased risk of de-
veloping PAD. Identifying novel risk factors for PAD
may help in the development of strategies for the pre-
vention and treatment of PAD in T2DM patients. Some
conventional risk biomarkers (smoking, hypertension,
hyperlipidemia, HbA1c level and CRP level) were inde-
pendently associated with PAD [20-22].
However, traditional risk factors do not entirely ex-
plain the excess risk of PAD in some subjects. Monitor-
ing non-conventional risk biomarkers for PAD in T2DM
may be particularly important for the prevention and
treatment of PAD. BNP levels are known to be elevated in
T2DM patients with asymptomatic diastolic dysfunction[23]. It has been acknowledged that subjects with higher
BNP levels are more likely to have conventional cardiovas-
cular risk factors (e.g., hypertension [24], ischemic stroke
[25,26], and chronic kidney disease [27]). However, BNP
levels are independent of cardiac function and cardiovas-
cular factors [28]. BNP release can be stimulated by vari-
ous factors, including inflammatory cytokines [29] and
renal impairment [30]. All of our subjects had a clear diag-
nosis of T2DM and those with diabetic complications that
could affect the metabolism of BNP were excluded or lim-
ited. In our study cohort, the high morbidity of PAD was
positively correlated with the BNP levels even after adjust-
ment for other risk factors. Subjects in the highest quartile
of the BNP level had a 1.25-fold increased risk of develop-
ing PAD compared with subjects in the lowest quartile
(first quartile) of the BNP levels. There were a significantly
increased risk for patients in the third quartile of the BNP
levels but not for patients in the second quartile, suggest-
ing a possible threshold effect of the BNP levels for the
prediction of PAD. Furthermore, our data showed that a
1-SD increase in the BNP levels were associated with a
1.16-fold increased risk of PAD after adjustment for the
known risk factors for PAD. The BNP levels were also
Figure 2 The predictive value of BNP levels for PAD can be reflected in ROC plots. A. BNP levels could be of use as predictive marker for
PAD. B. Comparison of the assessment of the likelihood of the presence of PAD between models with or without BNP.
Jin et al. BMC Endocrine Disorders 2014, 14:27 Page 5 of 7
http://www.biomedcentral.com/1472-6823/14/27inversely correlated with the ABI (r = −0.453, p =
0.033). It has been suggested that cardiac endocrine
function is more greatly activated in PAD patients than
in non-PAD patients [31], which may be why one can
predict future coronary artery disease or CVD events
in PAD patients with higher BNP levels [32]. Higher
BNP levels have been associated with lower functional
capacity in the vascular system [33]. Hence, consider-
ation of BNP levels is important for improved predic-
tion of PAD in T2DM patients without overt CVD.
The mechanisms through which the BNP levels and
PAD are associated are not clear. Studies have shown
that the natriuretic peptide family may have a role as
anti-migration factors for vascular smooth muscle cells
[34]. They also have beneficial effects in T2DM with
PAD because natriuretic peptides can promote angio-
genesis, modify the function of vascular endothelial
cells, reduce cardiac load, and improve blood supply to
the legs owing to their diuretic and vasodilatory effects
[35-37]. In Wistar rats, pretreatment with BNP can at-
tenuate the excessive production of radical oxygen spe-
cies [38]. Various studies have indicated that BNP has
aprotective role in vascular disease, butour data sup-
port the notion that higher BNP levels predispose to
PAD development in T2DM. However, thesediffering
results may not be contradictory because Kuhn et al.
[39] found that BNP is expressed in activated satellite
cells within ischemic muscle, and suggested that local-
ized BNP elicited protective endothelial effects. How-
ever, because of the impairment of BNP receptors in
atherosclerosis or ischemic vascular disease [40], the
protective effect of BNP is weakened [41], and BNP
levels are increased in response to the severity of ische-
mia as a protective effect. Nevertheless, the productionand secretion of BNP is the result of a complex inte-
gration among mechanical, chemical, hemodynamic,
humoral, ischemic, and inflammatory inputs in PAD
[31,42], and the specific mechanism remains to be elu-
cidated. BNP is likely to be a new therapeutic strategy-
for T2DM patients with PAD.
Some potential limitations of our study should be
noted. First, BNP levels were measured at a single time
point for each patient. Second, we focused on a se-
lected patient cohort hospitalized in an endocrinology
department in a single center, and whether the conclu-
sions can be generalized to other institutions requires
multicenter studies. Third, the ABI is not the “gold
standard” to diagnose PAD. Thus, comparison of BNP
levels with the ABI to evaluate PAD due to atheroscler-
osis may not be an optimal method. Further detailed
studies are required to investigate the association be-
tween BNP levels and PAD.Conclusions
Higher BNP levels (even in the normal range) are associ-
ated with a higher prevalence of PAD in T2DM patients.
Routine measurement of BNP levels can improve the
predictive ability of PAD in T2DM patients.
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